Invention Grant
- Patent Title: Rewiring aberrant cancer signaling to a therapeutic effector response with a synthetic two-component system
-
Application No.: US16400976Application Date: 2019-05-01
-
Publication No.: US11939609B2Publication Date: 2024-03-26
- Inventor: Hokyung Chung , Michael Z. Lin
- Applicant: The Board of Trustees of the Leland Stanford Junior University
- Applicant Address: US CA Stanford
- Assignee: The Board of Trustees of the Leland Stanford Junior University
- Current Assignee: The Board of Trustees of the Leland Stanford Junior University
- Current Assignee Address: US CA Stanford
- Agency: Bozicevic, Field & Francis LLP
- Agent Jenny L. Buchbinder
- Main IPC: A61K48/00
- IPC: A61K48/00 ; A61P35/00 ; C07K14/47 ; C07K14/535 ; C12N9/22 ; C12N9/50 ; C12N15/11 ; C12N15/86 ; A61K38/00 ; C12N15/113
Abstract:
Compositions and methods for targeted treatment of cancer are disclosed. In particular, the invention relates to methods of targeting anti-cancer therapy to cells exhibiting aberrant signaling associated with cancer pathogenesis by administering synthetic signaling proteins that couple detection of an oncogenic signal to release of therapeutic agents into cancerous cells.
Public/Granted literature
Information query
